In terms of conflicting pieces in audits, I met earlier today with some researchers on translational research on drugs, where the pharmaceutical companies won't invest if they're in a country where they're not making money. You have conflicting programs that will also somehow have to be sorted out.
I think I'm out of time. I just put that as another one. The opportunity is how we manage the conflicting programs.